Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

XERS 01.06.2025

Full Press ReleaseSEC FilingsOur XERS Tweets

About Gravity Analytica

Recent News

  • 01.10.2025 - Xeris Expects to Exceed Full-Year 2024 Financial Guidance
  • 01.06.2025 - Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Recent Filings

  • 01.10.2025 - 8-K Current report
  • 01.10.2025 - EX-99.1 EX-99.1
  • 01.07.2025 - 4 Statement of changes in beneficial ownership of securities

CHICAGO--(BUSINESS WIRE)--Jan. 6, 2025--Xeris Biopharma Holdings, Inc.(Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that onJanuary 2, 2025, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 181,500 shares of its common stock to 19 new employee(s) under Xeris’ Inducement Equity Plan.

Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The restricted stock units will vest over a period of three years in equal annual installments and are subject to the employees’ continued employment with Xeris or one of its subsidiaries. All equity awards are subject to the terms and conditions of Xeris’ Inducement Equity Plan and forms of award agreements covering the grants.

About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection of levothyroxine for hypothyroidism as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners.

Xeris Biopharma Holdingsis headquartered inChicago, IL.For more information, visitwww.xerispharma.com, or follow us onX,LinkedIn, orInstagram.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20250106342979/en/

Allison WeySenior Vice President, Investor Relations and Corporate Communicationsawey@xerispharma.com

Source:Xeris Biopharma Holdings, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com